<DOC>
	<DOCNO>NCT00651404</DOCNO>
	<brief_summary>To compare efficacy ezetimibe 10 mg add daily ongoing treatment atorvastatin 10 mg daily versus ezetimibe placebo add daily ongoing treatment atorvastatin 10 mg daily reduce concentration LDL-cholesterol ( LDL-C ) endpoint 6 week treatment .</brief_summary>
	<brief_title>Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone Subjects With Primary Hypercholesterolemia ( Study P03406 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>&gt; =18 year &lt; = 75 year age LDLC concentration &gt; = 2.6 mmol/L ( 100 mg/dL ) &lt; = 4.1 mmol/L ( 160 mg/dL ) use Friedewald calculation available time randomization Visit 3 ( Baseline Visit ) triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) Baseline Visit document coronary heart disease currently take atorvastatin 10 mg daily history take 80 % daily dose precede 6 week prior Visit 3 liver transaminase ( ALT , AST ) &lt; 50 % upper limit normal , active liver disease , CK &lt; 50 % upper limit normal Baseline Visit . cholesterol lower diet exercise program least 4 week prior study , stable weight history . woman receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week continue regimen study . woman nonchildbearing potential use acceptable method birth control . subject must free clinically significant disease hyperlipidemia coronary heart disease would interfere study evaluation . Subjects whose body mass index &gt; =30 kg/sqm baseline . Subjects consume &gt; 14 alcoholic drink per week . Any condition situation , opinion investigator , might pose risk subject interfere participation study . Women pregnant nursing . Subjects observed designate washout period prohibit medication ( eg , potent inhibitor CYP3A4 , prescription overthecounter agent know low lipid level , corticosteroid ) , stable regimen cardiovascular agent &lt; 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>